The silent treatment

Julie Clayton

Nature, 2004, vol. 431, issue 7008, 599-601

Abstract: Biotech firms are vying to harness the potential of RNA interference. But will its impact be in finding new disease targets, or in RNA-based drugs? Julie Clayton investigates.

Date: 2004
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/431599a Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:431:y:2004:i:7008:d:10.1038_431599a

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/431599a

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().